Business, energy, technology, markets and global industry news from Business News Today

Epetraborole

PharmaDeviceNews Epetraborole
AN2 Therapeutics is advancing a broader boron-based drug pipeline, with Phase 2 programs targeting polycythemia vera, Mycobacterium abscessus lung disease and Chagas disease as the company enters a critical clinical execution period. Representative image.
Pharma & Biotech

AN2 Therapeutics is betting on three Phase 2 programs, but can its boron pipeline deliver after epetraborole’s MAC setback?

AN2 Therapeutics is advancing three Phase 2 programs as epetraborole moves into PV and AN2-502998 approaches a Chagas proof-of-concept test.

Read More
What epetraborole’s hematocrit effects could mean for the future treatment landscape in polycythemia veraWhat epetraborole’s hematocrit effects could mean for the future treatment landscape in polycythemia vera
Pharma & Biotech

Can AN2 Therapeutics reposition epetraborole for polycythemia vera and reshape hematocrit control strategies?

AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.

Read More